The joint studies showed some improvement in a few biological measures of the disease, but most of the changes were small and not enough to make a difference in delaying cognitive decline.
Details of failed studies cast pall on Novo Nordisk's GLP
The Economy Times Industry2 hrs ago
126


The Times of India
YourTango Horoscope
KSNB Local4 Central Nebraska
Tribune Chronicle
Vogue
The Daily Beast
Associated Press US News